---
title: "Rocket Pharmaceuticals, Inc. (RCKT.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/RCKT.US.md"
symbol: "RCKT.US"
name: "Rocket Pharmaceuticals, Inc."
industry: "Biotechnology"
datetime: "2026-05-19T22:42:05.708Z"
locales:
  - [en](https://longbridge.com/en/quote/RCKT.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/RCKT.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/RCKT.US.md)
---

# Rocket Pharmaceuticals, Inc. (RCKT.US)

## Company Overview

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops ex vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red de Enfermedades Raras, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and Temple University.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.rocketpharma.com](https://www.rocketpharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.60 | 222 | - | - | - |
| PB | 1.41 | 130 | 1.40 | 1.14 | 0.88 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-12T04:00:00.000Z

Total Analysts: **13**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 5 | 38% |
| Hold | 6 | 46% |
| Underweight | 1 | 8% |
| Sell | 1 | 8% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.92 |
| Highest Target | 16.00 |
| Lowest Target | 3.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/RCKT.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/RCKT.US/norm.md)
- [Related News](https://longbridge.com/en/quote/RCKT.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/RCKT.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**